INTRODUCTION {#s1}
============

Malignant gliomas are an aggressive form of brain cancer, in both humans and dogs, with a poor prognosis despite surgery, chemotherapy and ionising radiation \[[@R1]--[@R3]\]. In humans, the median survival time after diagnosis of glioblastoma multiforme (GBM), the most common form of malignant glioma, is 15 months \[[@R4]\]. There is a clear need for more effective strategies for the treatment of GBM, but many drug trials fail because the pre-clinical animal models do not sufficiently represent the human disease \[[@R5], [@R6]\]. The size and structure of the dog\'s brain, histopathology and molecular characteristics of canine GBM, as well as the presence of the intact immune system, all support canine brain tumours as naturally occurring models of human glioma \[[@R5], [@R7]\]. This comparative approach may yield translational advancement for novel diagnostic, drug and therapeutic studies.

In both human and veterinary medicine radiotherapy is a key treatment modality for brain tumours, but the efficacy is limited by radioresistance \[[@R8]\]. Recently, it has been established that in many types of cancer the bulk of the cells that make up the tumour are derived from a small population of cancer stem cells (CSCs) \[[@R9]\]. Glioma CSCs share characteristics with normal stem cells such as expression of neural stem cell markers, properties of self-renewal, extensive proliferation, and the ability to differentiate into more mature neural lineages. These cells have also been assigned a role in tumour angiogenesis and treatment resistance, and upon intercranial transplantation onto immunocompromised mice can successfully seed new tumours \[[@R10]--[@R15]\]. Thus, CSCs are likely to be responsible for initiation, progression and relapse of malignant gliomas, as conventional therapies that target the bulk of the tumour will fail to cure the disease because the CSCs will be unaffected and are able to recapitulate the tumour. Therefore it is imperative to target CSCs in the treatment of this disease.

There are genetic aberrations associated with GBM; amplification of epidermal growth factor receptor (EGFR) is a frequent finding that has been described in 40-50% of all human glioblastomas \[[@R16]--[@R18]\]. EGFR is a tyrosine kinase that is activated by ligand binding, thereby inducing receptor dimerization and auto-phosphorylation of key tyrosine residues. EGFR signaling affects many cellular events including cell survival, proliferation, differentiation, metabolism, and migration \[[@R7], [@R19]\]. In response to irradiation, EGFR promotes intracellular downstream signaling involving, among others, mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K), these pathways mediate cell survival and radio-resistance \[[@R20], [@R21]\]. EGFR also directly interacts with and enhances the activity of DNA-PK. DNA-PK plays a central role in non-homologous end joining double strand break repair \[[@R22], [@R23]\]. Activation of EGFR thereby exerts a protective function against DNA damage and promotes tumour cell survival.

In this study, we isolated and characterised CSCs from a canine and a human glioma cell line and showed that these cells express stem cell markers; are more invasive; more tumourigenic and more resistant to the cytotoxic effects of chemotherapy and ionising radiation, in comparison to their non-stem cell counterparts. Global transcriptional analysis of these CSCs revealed that they have a distinct gene expression profile consisting of over 10,000 significant differences, compared to non-CSCs. Moreover, a number of the most upregulated genes in CSCs are activators of EGFR. Concurrently we showed that CSCs have enhanced basal activation of the EGFR pathway that can be inhibited by the EGFR tyrosine kinase inhibitor, gefitinib. Our findings demonstrated that gefitinib treatment enhanced radio-sensitivity of both canine and human glioma CSCs, enabling this resistant, tumourigenic population of cells to be effectively targeted by ionising radiation. This data further validates canine glioma as a model for the human disease supporting the development of new therapeutic strategies in both human and veterinary medicine.

RESULTS {#s2}
=======

Glioma stem cells express stem cell markers, increased invasiveness and increased tumourigenicity {#s2_1}
-------------------------------------------------------------------------------------------------

In this study we have utilised an established serum-free cell culture system that favours the proliferation of undifferentiated cells thereby enriching for CSCs, which grow as spheres \[[@R13]\]. Expression of the stem cell marker CD133 was characterised by magnetic cell sorting \[[@R13]\]. Cells from the canine glioma cell line J3T and the human glioma cell line LN18 contain a small subpopulation of CD133+ cells (1.17 ±0.58 % (*n* = 8) and 2.07 ±0.43 % (*n* = 4), respectively), that are significantly better at forming spheres (Figure [1A and 1B](#F1){ref-type="fig"}), and express higher levels of the embryonic stem cells markers *Oct4*, *Nanog* and *STAT3* (Figure [1C](#F1){ref-type="fig"}) than CD133- cells (similar results were obtained for LN18 CSC, data not shown).

![Isolation and characterisation of glioma cancer stem cells (CSCs)\
A small population of CD133+ cells exists in canine glioma J3T cell line **(A)** and the human glioma LN18 cell line **(B)** and readily form spheres compared to CD133- cells. Data are representative of three independent experiments ±SD (\**p* \< 0.001). Images were taken at 40x magnification. **(C)** Reverse transcriptase (RT)-PCR analysis of embryonic stem cell markers: *Nanog*, *Oct4*, *STAT3*, and *β-actin* gene expression levels of J3T CD133+ and CD133- cells. **(D)** Western blots analysis of cell lysates derived from J3T adherent cells and spheres for markers of EMT: E-cadherin, fibronectin, β-catenin, with β-actin as a loading control. 30 μg was loaded per lane **(E)** J3T CSCs show an increased invasive potential *in vitro*. Invasive ability of J3T adherent cells and spheres was analysed using a collagen based invasion assay. **(F)** Invading cells were quantified by measuring the optical density at 560 nm (\*\* *p* \< 0.005). **(G)** Glioma CSCs are enriched for higher tumourigenicity *in vivo*. Disassociated J3T spheres and adherent cells were inoculated directly onto the chorioallantoic membrane of a chicken embryo at day 7 of development. All cells were fluorescently labelled and imaged 3 days after inoculation.](oncotarget-08-72494-g001){#F1}

The metastatic potential of CSCs, which is the ability of a CSC to migrate from the tumour microenvironment and subsequently invade and attach at a secondary site, is proposed to be mediated by the epithelial-to-mesenchymal transition (EMT) \[[@R24], [@R25]\]. Here we show that J3T spheres have a mesenchymal phenotype, whereby expression of E-Cadherin and β-catenin was significantly decreased, and that of Fibronectin was significantly increased compared to adherent cells (Figure [1D](#F1){ref-type="fig"}), and that CSCs are much more invasive *in vitro* (Figure [1E and 1F](#F1){ref-type="fig"}) (similar results were obtained for LN18 CSC, data not shown). To determine if spheres were more likely to form tumours *in vivo* than adherent cells, we utilised the chicken embryo chorioallantoic membrane (CAM) model: the CAMs of day 7 chicks were inoculated with either fluorescently labelled dissociated spheres or adherent cells. At day 10 of development 3-dimensional tumours were visible in 100% of membranes inoculated with dissociated spheres but not adherent cells. These micro-tumours were visualized under the fluorescence microscope; sphere cells were brightly fluorescent and had radiated out from the 3-dimensional tumour growths, invading the surrounding blood vessels of the CAM. In contrast, adherent cells were localised to the initial site of inoculation (Figure [1G](#F1){ref-type="fig"}). Therefore CSCs have a greater *in vivo* tumourigenic capacity than non-CSCs cells.

CSCs exhibit greater resistance to radiation-induced cytotoxicity {#s2_2}
-----------------------------------------------------------------

To determine whether spheres cells preferentially survive after treatment with external beam radiation, spheres derived from J3T and LN18 cell lines, were disassociated into single cells and treated with increasing doses of ionising radiation. Clonogenic survival was determined: J3T and LN18 spheres demonstrated a significantly increased resistance to radiation-induced replicative cell death compared to non-CSC adherent cells (Figure [2A and 2E](#F2){ref-type="fig"}, respectively). Similar results were obtained when CSCs were isolated by expression of CD133 (Figure [2B and 2F](#F2){ref-type="fig"}, respectively). Cell viability was assayed 48 hours after treatment: J3T non-CSCs showed a dose-dependent decrease in cell viability whereas CSCs were inherently resistant to the cytotoxic effect of radiation (Figure [2C and 2D](#F2){ref-type="fig"}), and therefore in a physiological setting may contribute to tumour repopulation.

![CSCs are resistant to radiation treatment\
Analysis of colony forming ability was assayed after J3T adherent cells and spheres **(A)**, and CD133 sorted cells **(B)** were treated with increasing doses of ionising radiation. Cell viability of J3T adherent and spheres **(C)** and CD133 sorted cells **(D)** was assayed 48 hours after treatment. Analysis of colony forming ability was assayed after LN18 adherent cells and spheres **(E)**, and CD133 sorted cells **(F)** were treated with increasing dose of ionising radiation. (\* *p* \< 0.005).](oncotarget-08-72494-g002){#F2}

Treatment of CSCs with doxorubicin increases the size of the CSC population and highlights defects in activation of p53 {#s2_3}
-----------------------------------------------------------------------------------------------------------------------

Similarly, J3T CD133+ cells were resistant to the cytotoxic effect of the chemotherapy drug, doxorubicin. Doxorubicin is an anti-tumour antibiotic DNA damaging agent and is commonly used in veterinary and human cancer chemotherapy protocols. Here, CD133+ and CD133- cells were treated with increasing concentrations of doxorubicin and cell viability was assayed 48 hours after treatment. CD133+ cells demonstrated significantly increased resistance to doxorubicin induced cell death compared to CD133- cells (Figure [3A](#F3){ref-type="fig"}). Doxorubicin treatment also increased the size of the CD133+ population in a dose dependent manner (Figure [3B](#F3){ref-type="fig"}), further supporting the finding that CSCs are resistant to doxorubicin treatment. To determine if resistance of CSCs to DNA damaging agents was due to defects in the p53 pathway, we treated CD133 sorted cells with doxorubicin and by western blotting analysed protein expression of key members of the pathway. In response to doxorubicin, CD133- cells showed a transient increase in p53 levels and phosphorylation of p53 serine-15, an ATM target that is associated with activation of p53 transcriptional activity \[[@R26]\], and of the p53 transcriptional target MDM2 at 4 hours post-treatment (Figure [3C](#F3){ref-type="fig"}). Levels of γH2AX, an ATM target and a marker of DNA double strand breaks \[[@R27]\], similarly increased 4 hours post-treatment in CD133- cells (Figure [3C](#F3){ref-type="fig"}), whereas, in CD133+ cells induction of γH2AX, p53, phosphorylation of p53 serine-15, and induction of MDM2 was markedly reduced (Figure [3C](#F3){ref-type="fig"}). The primary role of p53 is as a stress-activated transcription factor therefore reduced p53 activity in CSCs may be linked to p53 protein localization \[[@R28]\]. In untreated non-CSC adherent cells, p53 protein was detected at a low level and was located in the cytosolic and nuclear fractions, whereas in untreated CSCs p53 protein levels were relatively low and associated with the nuclear fractions (Figure [3D](#F3){ref-type="fig"}). Upon DNA damage, the p53 protein levels in adherent cells increased in both the nuclear fractions, whereas in CSCs p53 protein levels and subcellular localisation remain unchanged (Figure [3D](#F3){ref-type="fig"}). Similarly, phosphorylation of p53 at serine-15 was undetectable in untreated adherent and sphere cells, but upon DNA damage a high level of phosphorylation of p53 at serine-15 in the nuclear fractions of adherent cells was detectable, whereas there was a low level of phosphorylation of p53 at serine-15 detected in CSCs (Figure [3D](#F3){ref-type="fig"}). The total protein content of each fraction was evaluated qualitatively by coomassie staining (Figure [3D](#F3){ref-type="fig"}).

![Doxorubicin treatment enriches CSCs subpopulation and highlights that in CSCs p53 activity is attenuated and aberrantly localised within the cell\
**(A)** Cell viability of MACS-sorted J3T CD133+ and CD133- cells was assayed 48 hours after treatment with increasing doses of doxorubicin (\* *p* \< 0.005). **(B)** J3T cells were treated with the indicated doses of doxorubicin and the percentage CD133+ cells was determined 24 hours post-treatment. **(C)** CD133+ and CD133- cells were treated with doxorubicin and harvested 4 hours after treatment. Cell lysates were probed for the expression of phosphorylation of p53 at serine-15, MDM2, γH2AX and β-actin as a loading control. 30 μg was loaded per lane. **(D)** The subcellular localisation of p53, in J3T adherent cells and spheres, was determined 4 hours post-treatment with the indicated doses of doxorubicin by western blotting. Proteins were extracted according to their subcellular localisation: F1, cytosolic; F2, membranes/organelles; F3, nucleus; F4, nucleus; F5, cytoskeleton. 30 μg was loaded per lane. Coomassie staining (CM) confirmed that protein expression profiles from each fraction were distinct, 5 μg was loaded per lane.](oncotarget-08-72494-g003){#F3}

Global analysis of gene expression reveals significant differences in the molecular profiles of CSCs and non-CSCs {#s2_4}
-----------------------------------------------------------------------------------------------------------------

We performed gene expression profiling of J3T CSCs and non-CSCs, minus (0 Gy) or plus (5 Gy) external beam radiation, using the Affymetrix GeneChip® Canine 2.0 Array. Untreated CSCs, represented by sphere cells, differentially expressed (i.e. up- or down regulated \>2-fold with a false discovery rate (FDR) of 0.05) 15,193 genes compared to non-CSCs. To obtain a manageable number of gene differences, the FDR was decreased to 0.005. Under these parameters, 10,358 genes were differentially expressed in CSCs compared to non-CSCs. A similar number of gene expression changes were observed between CSCs and non-CSCs post-irradiation treatment (Table [1](#T1){ref-type="table"}). Interestingly, radiation induced more mRNA changes in non-CSCs (265) compared to CSCs (45). Principle component analysis shows a distinct separation of CSC and non-CSC populations (Figure [4A](#F4){ref-type="fig"}) and the heatmap shows that non-irradiated and irradiated CSCs cluster more closely than with non-irradiated and irradiated non-CSCs (Figure [4B](#F4){ref-type="fig"}). Further pathway analysis showed that the differential expression profile of non-irradiated CSCs encompassed genes involved in a variety of biological processes and diseases including cell cycle regulation, protein synthesis, cell growth, proliferation, DNA repair, apoptosis, and cancer (Figure [4C](#F4){ref-type="fig"}). Significantly, genetic disorder and cancer were the top diseases identified in the analysis (Table [2](#T2){ref-type="table"}), indicating that gene expression profiles associated with cancer are more prevalent in the CSC population than the non-CSCs. The top ten upregulated genes in CSCs compared to non-CSCs are shown in Table [3](#T3){ref-type="table"}. Similar results were obtained for irradiated CSCs compared to irradiated non-CSCs (data not shown). Validation of the microarray was carried out by qRT-PCR (Figure [4D](#F4){ref-type="fig"}).

###### Primer sequences for the amplification of RT-PCR products from canine cells

  Gene        Forward primer (5′-3′)    Reverse primer (5′-3′)     Product size
  ----------- ------------------------- -------------------------- --------------
  *Oct4*      CTCTGCAGCCAATCAACCACAA    GGAGAGGGGGATGAGAAGTACAAT   237 bp
  *Nanog*     CTATAGAGGAGAGCACAGTGAAG   GTTCGGATCTACTTTAGAGTGAGG   160 bp
  *STAT3*     GTGGAGAAGGACATCAGCGGTAA   AACTTGGTCTTCAGGTATGGGGC    250 bp
  *β-Actin*   CATGTTTGAGACCTTCAACACCC   GCCATCTCTTGCTCGAAGTCCAG    229 bp

![Gene expression analysis of canine glioma stem cells\
**(A)** A three-dimensional representation of a principle component analysis of expression microarray data derived from untreated J3T adherent cells (0 Gy), irradiated adherent cells (5Gy), untreated spheres (0 Gy) and irradiated spheres (5 Gy). **(B)** Hierarchical clustering analysis of the expression data (cut off *p*-value of 0.005). Expression values are represented by colours: blue squares represent low-expressed genes, red squares represent high-expressed genes. **(C)** Biological process analysis of differentially expressed genes in J3T spheres compared to adherent cells (FDR = 0.005). **(D)** Validation of microarray with qRT-PCR.](oncotarget-08-72494-g004){#F4}

###### Primer sequences for the amplification of qRT-PCR products from canine cell lines

  Gene        Forward primer (5′-3′)      Reverse primer (5′-3′)
  ----------- --------------------------- --------------------------
  *TNFAIP6*   ACGGTTTTGTGGGAAGGTACT       TTTGGAAACCTCCCGCTGTC
  *EDNRA*     GAATTACTTAGTTTCTTGCGTCTCA   GGACTGGTAACAGCAACAGC
  *NGR1*      CTGGTGATCGCTGCCAAAAC        AGAGCTCCTCCGCTTCCATA
  *IL8*       TGTTGCTCTCTTGGCAGCTT        CGGATCTTGTTTCTCAGCCTTCTT
  *MRPS7*     AGTGCAGGGAGAAGAAGCAC        CAGCAGCTCGTGTGACAACT
  *GAPDH*     GGGAAGATGTGGCGTGAC          GAAGGCCATGCCAGTGAG

###### The number of differentially expressed genes between the indicated cell populations of J3T spheres (SPH) and adherent (ADH) cells

                                p = 0.05   p = 0.005
  ----------------------------- ---------- -----------
  J3T SPH V ADH (0 Gy)          15,193     10,358
  J3T SPH V ADH (5 Gy)          13,634     8,841
  J3T SPH (5 Gy) V SPH (0 Gy)   239        45
  J3T ADH (5 Gy) V ADH (0 Gy)   1338       265

EGFR is constitutively active in CSCs {#s2_5}
-------------------------------------

Activators of the EGFR pathway, including EDNRA, CXCR7, IGFBP2 and EGR1, dominated the top 10 upregulated genes in CSCs compared to non-CSCs, as identified by microarray analysis. Although elevation of EGFR gene expression was not detected, CSCs do exhibit a higher basal level of EGFR protein that is constitutively phosphorylated at serine-1047 and tyrosine-1173. Constitutive phosphorylation of AKT, a downstream target of EGFR, indicates that the EGFR pathway is constitutively active in CSCs in contrast to non-CSCs (Figure [5A](#F5){ref-type="fig"}). To determine the effect of EGFR inhibition J3T adherent cells and spheres were treated with gefitinib, a selective inhibitor of the tyrosine kinase site in the catalytic domain of EGFR. In CSCs, gefitinib inhibited phosphorylation of EGFR at serine-1047 and tyrosine-1173, and inhibited activation of AKT. The total levels of EGFR and AKT were unaffected until 6 hours post-treatment where there is a decrease in EGFR levels in both cell populations. Non-CSCs showed no basal activation of the either the EGFR or AKT pathway (Figure [5A](#F5){ref-type="fig"}).

![EGFR is constitutively active in CSCs\
**(A)** J3T adherent and sphere cells were treated with 5 μM gefitinib and harvested over the indicated time course. Expression of EGFR, phosphorylation of EGFR at serine-1047 and tyrosine-1173, AKT, phosphorylation of AKT, and β-actin as a loading control. 20 μg was loaded per lane. Comparison of the effect of increasing doses of gefitinib on proliferation of adherent and spheres of J3T **(B)** and LN18 cells **(C)**. Cells were treated with increasing doses of gefitinib and cell viability was assayed 48 hours post treatment.](oncotarget-08-72494-g005){#F5}

Inhibition of EGFR enhanced CSCs chemosensitivity {#s2_6}
-------------------------------------------------

Surprisingly, gefitinib treatment alone had no significant effect on the cell viability of both canine and human CSCs (Figure [5B and 5C](#F5){ref-type="fig"}, respectively), but enhanced the proliferation of non-CSCs until doses exceeding 5 μM were used, whereby cell viability, of all cell populations, decreased in a dose dependent manner. This was the dose of gefitinib selected for further experiments.

To determine the effect of gefitinib on chemosensitivity, J3T adherent and sphere cells were pre-incubated with gefitinib for 24 hours prior to treatment with increasing doses of doxorubicin for 48 hours, before cell viability was analysed. Combinational gefitinib and doxorubicin treatment had no effect on adherent non-CSCs (Figure [6A](#F6){ref-type="fig"}). However, in CSCs inhibition of EGFR enhanced the sensitivity of these cells to the cytotoxic effects of doxorubicin compared to control (Figure [6B](#F6){ref-type="fig"}). To substantiate these findings we analysed the clonogenic survival of doxorubicin treated cells with and without gefitinib. J3T CSCs are inherently more resistant to doxorubicin than non-CSCs in the absence of EGFR inhibition, however gefitinib enhanced the chemosensitivity of CSCs to a level comparable to non-CSCs (Figure [6C](#F6){ref-type="fig"}). Interestingly, gefitinib alone reduced the colony forming ability of non-CSCs but had no effect on CSCs, until the cells were challenged with chemotherapy (Figure [6C](#F6){ref-type="fig"}). Similar results were obtained with human LN18 cells (Figure [6D](#F6){ref-type="fig"}).

![Gefitinib decreases CSC resistance to doxorubicin\
J3T adherent **(A)** and spheres **(B)** were pre-treated with either a DMSO control or gefitinib (5 μM) for 24 hours, incubated with the indicated doses of doxorubicin and cell viability was assayed 48 hours post-doxorubicin treatment. Colony forming ability of adherent and spheres derived from J3T **(C)** and LN18 **(D)** cell lines was assayed after cells had been pre-treated with either a DMSO control or gefitinib (5 μM) for 24 hours prior to doxorubicin treatment (\* *p* \< 0.005, \*\* *p* \< 0.001).](oncotarget-08-72494-g006){#F6}

Inhibition of EGFR sensitises glioma CSCs to radiation-induced cytotoxicity {#s2_7}
---------------------------------------------------------------------------

As radiation treatment is the principal modality for treating glioma, we tested the combinational effect of EGFR inhibition and radiation on cell proliferation and clonogenic survival. Canine J3T (Figure [7A](#F7){ref-type="fig"}) and human LN18 (Figure [7B](#F7){ref-type="fig"}) adherent cells and spheres were treated with increasing doses of gefitinib (0 μM -- 10 μM) and increasing doses of ionising radiation (0 Gy -- 5 Gy). Gefitinib alone had no significant effect on the cell viability of either cell population (Figure [7A](#F7){ref-type="fig"} i) and 7B i)) until doses exceeding 5 μM were used. However, gefitinib in combination with ionizing radiation doses of 2.5 Gy (Figure [7A](#F7){ref-type="fig"} ii) and 7B ii)) and 5 Gy (Figure [7A](#F7){ref-type="fig"} iii) and 7B iii)), significantly increased the sensitivity of both CSCs and non-CSCs to radiation-induced cell death in a dose-dependent manner. Consistent with previous results, CSCs were more resistant to the effects of EGFR inhibition than non-CSCs ((Figure [7A, 7B](#F7){ref-type="fig"} ii) and iii)). Clonogenic survival analysis is a longer-term assay that measures cell reproductive death after treatment, and here shows that non-CSCs were unaffected by pre-treatment with gefitinib prior to radiation at the indicated doses (Figure [7C](#F7){ref-type="fig"} i) and 7D i)). Whereas inhibition of EGFR sensitised CSCs to the cytotoxic effects of increasing doses of ionising radiation (Figure [7C](#F7){ref-type="fig"} ii) and 7D ii)). These results indicate that combinational targeting of EGFR may be an effective method to overcome the intrinsic insensitivity to chemotherapy and radiation of CSCs.

![Inhibition of EGFR sensitises glioma CSCs to radiation-induced cytotoxicity\
J3T **(A)** and LN18 **(B)** adherent and spheres were treated with the indicated doses of gefitinib for 24 hours prior to treatment with either 0 Gy (i), 2.5 Gy (ii), or 5 Gy (iii), cell viability was assayed 48 hours post-irradiation treatment. Colony forming ability of adherent (i) and spheres (ii) derived from J3T **(C)** and LN18 **(D)** cell lines was assayed after cells had been pre-treated with either a DMSO control or gefitinib (5 μM) for 24 hours prior to treatment with indicated doses of irradiation (\* *p* \< 0.005).](oncotarget-08-72494-g007){#F7}

DISCUSSION {#s3}
==========

GBM, the most aggressive and lethal primary brain tumour in both humans and dogs, portends a poor prognosis despite surgery, chemotherapy, and radiation \[[@R2], [@R4], [@R5]\]. GBM is characterized by a high degree of heterogeneity that reflects the presence of multiple subpopulations of cancer cells within the same tissue \[[@R29], [@R30]\]. Recurrence of tumour growth is attributed to the presence of treatment-resistant CSCs \[[@R8]\]. Future targeting of these CSCs is therefore essential in the treatment of this disease. CSCs have been isolated from primary cases of human \[[@R8], [@R10]--[@R13], [@R15]\] and canine GBM \[[@R14]\].

To date there are no bona fide cell surface markers available to distinguish non-CSCs from CSCs. CD133, which is expressed on hematopoietic \[[@R31]\] and neural stem cells \[[@R32]\], is widely used as a CSC marker in several tumours, including GBM, where cell sorting for CD133 expression can enrich for cells with tumourigenic potential \[[@R12], [@R13]\]. However, conflicting findings have called into question the utilization of this marker in brain tumours: there is a high variability of CD133 expression in GBM (from 1% to 60%); and GBM stem cells not expressing CD133, which are able to self-renew and regenerate tumours in the xenotransplantation assay, have been identified \[[@R33]--[@R35]\]. A recent study showed that neurospheres are composed of CD133-positive and CD133-negative cells, and although CD133-negative cells do not express CD133 on the plasma membrane they do show diffuse cytoplasmic staining \[[@R36]\]. Furthermore, the subcellular localization of CD133 is plastic: shuttling between the cytoplasm and plasma membrane in response to cues from the microenvironment. Brescia *et al* (2013) concluded that CD133 is essential to the maintenance and tumourigenic potential of GBM CSCs \[[@R36]\]. Due to the ambiguity of CD133 as a universal marker of CSCs, we choose the neurosphere assay as a surrogate for *in vitro* study of GBM CSCs. In the present study, we have demonstrated that rare sub-populations of cancer cells exist in established canine and human glioma cell lines, which possess several distinct functional properties of CSCs, including expression of CD133, *in vitro* self-renewal, increased invasiveness, preferential expression of embryonic stem cell markers and markers of EMT, and *in vivo* tumourigenic capacity.

We have also shown that CSCs are inherently resistant to chemotherapy, and due to this, doxorubicin treatment enhances the size of the CSC pool. Interestingly, CSCs lacked activation of the stress-activated transcription factor p53 and phosphorylation of γH2AX, an ATM target and a marker of DNA double strand breaks \[[@R26], [@R27]\]. This is consistent with human and mouse embryonic stem cells that lack the cell cycle checkpoint between G1 and S-phase and do not senesce after DNA damage, due to an inactive p53 pathway, which is to avoid severe depletion of the functional stem cell pool. Subsequent studies have highlighted that over-expression of p53 in ESCs leads to a suppression of self-renewal and induction of differentiation, and in the context of reprogramming, expression of wild-type p53 constrains iPSC generation *in vitro* \[[@R37]--[@R39]\]. Given that CSCs could arise from either the accumulation of genetic insults in normal stem cells or by dedifferentiation of existing differentiated cells, and that p53 is both a driver of differentiation and a barrier of dedifferentiation, our findings contribute to evidence that inactivation of p53 is a stem cell trait.

Global analysis of gene expression showed vast differences between J3T CSCs and non-CSCs, with 10,358 significant differences. Comparisons of non-irradiated and irradiated CSCs revealed fewer significant differences (45), than that of non-CSCs (265), indicating that CSCs may indeed have a dampened down DNA damage response, reflected by reduced activity of ATM and p53. Data mining for biologically relevant targets highlighted that activators of the EGFR pathway, including EDNRA \[[@R40]\], CXCR7 \[[@R41], [@R42]\], IGFBP2 \[[@R43]\] and EGR1 \[[@R44]\], are overexpressed in CSCs compared to non-CSCs. Even though EGFR itself was not overexpressed we showed that EGFR was constitutively active in CSCs and that this can be attenuated by treatment with the small molecule tyrosine kinase inhibitor, gefitinib. In humans EGFR is a potent driver of oncogenesis; over-expressed in a range of tumours; and is associated with worse overall survival \[[@R18], [@R45]\]. Similarly in dogs, there is significantly greater expression of EGFR in GBMs compared to other canine inter-cranial brain tumours that have been documented \[[@R46], [@R47]\]. In both neural stem cells and glioma CSCs activated EGFR signaling increases proliferation, survival, migration and blocks differentiation \[[@R7]\]. Here we show that inhibition of EGFR signaling alone had no effect on the viability of CSCs, however it does sensitise CSCs to the cytotoxic effects of chemotherapy and ionising radiation. In head and neck cancer resistance of tumour cells to radiotherapy has been shown to increase proportionally with EGFR expression, and it has been proposed that up-regulation of EGFR is a mechanism employed by cancer cells to circumvent the cytotoxic effects of radiotherapy \[[@R48], [@R49]\].

The effect of EGFR-targeted therapy has been extensively tested in preclinical human glioma models \[[@R50]--[@R52]\]. Small molecule tyrosine kinase inhibitors, including erlotinib and gefitinib, are well established in clinical practice for the treatment of lung carcinomas, yet showed a lack of activity in glioma \[[@R52]\]. An alternative approach is to use antibodies directed against EGFR, including cetuximab, nimotuzumab, and panitumumab, that prevent the binding of EGFR ligands to the receptor. Although these antibodies are clinically relevant in the treatment of advanced colorectal carcinoma \[[@R53], [@R54]\] and metastatic breast cancer \[[@R55], [@R56]\], their implementation against intracranial neoplasms are challenging due to the presence of the blood-brain barrier, which may preclude the penetration of the antibody to all parts of the tumour. This has been mirrored in the treatment of glioma patients with pharmacological inhibitors of EGFR or blocking antibodies that fail to show signs of activity, indicating that inhibition of EGFR alone is insufficient \[[@R57]--[@R59]\]. It is interesting to speculate that termination of EGFR signaling may lead to the acquisition of compensatory additional genetic events, such as the expression of alternative tyrosine kinase receptors, and that disruption of converging signaling pathways may help overcome resistance to EGFR inhibitors.

Several studies have previously suggested a sensitizing effect of inhibition of EGFR to radiation \[[@R23], [@R60]--[@R63]\]. Clinical trials to explore the combination of radiation therapy with inhibition of EGFR in patients with newly diagnosed glioblastoma failed to show an increase in survival compared to historical controls \[[@R64], [@R65]\]. Patients were not selected for these trials on the basis of high expression of EGFR. However gene amplification or expression of wild-type EGFR or expression of a mutant form called EGFR variant III (EGFRvIII) is found in approximately 40-50% of all human gliomas \[[@R16]\]. EGFRvIII arises from an in-frame deletion of exons 2-7 from the extracellular domain, leading to a loss of ligand binding potential, constitutive activation of the receptor and resistance to gefitinib \[[@R66]\]. Rather than global overexpression of EGFR throughout the tumour, our data in the J3T cell line shows that a minority population of CSCs do not over-express of EGFR but do have constitutive activation of EGFR compared to the bulk of the tumour cells, that can be attenuated by treatment with gefitinib. Successful targeting of CSCs is of paramount importance as these cells have been suggested to be responsible for the treatment resistance and recapitulating tumour growth in GBM patients. Radiotherapy is currently the key treatment modality for GBM, but efficacy is limited by radio-resistance that may be mediated by CSCs. We have shown that CSCs were significantly more resistant to chemotherapy and radiation than non-CSCs, and that inhibition of EGFR, by gefitinib, can sensitise both human and canine glioma CSCs to the cytotoxic effects of doxorubicin and radiation. Our data indicates that inhibition of EGFR has a role as part of a multimodal therapy in overcoming resistance of CSCs to conventional therapies.

MATERIALS AND METHODS {#s4}
=====================

Cell culture and sphere formation {#s4_1}
---------------------------------

The tumour cell lines used in this study were the canine glioma cell line J3T \[[@R67], [@R68]\], and human glioma cell line LN18 \[[@R69]\], both were obtained commercially (ATCC, Middlesex, UK). J3T cells were grown in Dulbecco\'s modified Eagle\'s medium (DMEM) (Invitrogen, Paisley, UK) supplemented with 10 % fetal bovine serum and 100 μg/ml streptomycin (Invitrogen, Paisley, UK). LN18 were grown in DMEM (Invitrogen, Paisley, UK) supplemented with 10 % fetal bovine serum and 100 μg/ml streptomycin.

For anchorage-independent culture, cells were plated as single cells in ultra-low attachment 6-well plates (Corning, CA, USA) at low cell density (1.5×10^4^ cells/ml). Cells were grown in serum-free conditional medium, which contained William\'s E Medium with GlutaMAX supplemented with putrescine (100 μM), sodium selenite (30 nM), transferrin (25 μg/ml), insulin (20 μg/ml) (Sigma Biochemicals, Dorset, UK), human recombinant bFGF (10 ng/ml) (Peprotech, NJ, USA). Additional bFGF (100 μg/ml) was added to the media every other day. All cell cultures were maintained at 37°C in a humidified CO~2~ incubator.

Magnetic cell sorting {#s4_2}
---------------------

Cells were labelled with CD133 microbeads and sorted using the Miltenyi Biotec CD133 cell isolation kit according to the manufacturer\'s protocol (Miltenyi Biotec, Surrey, UK). Briefly, cells were resuspended in 300 μl PBS solution (pH 7.2, 0.5% BSA, 2 mM EDTA) per 10^8^ cells. Then blocking reagent FcR (100 μl/10^8^ cells; Miltenyi Biotec, Surrey, UK) and CD133 microbeads (100 μl/10^8^ cells) were added and mixed at 4°C for 30 minutes with rotation. Cells were washed in 20x volume with PBS solution. The pellet was resuspended in 500 μl PBS solution and added to a pre-washed magnetic separation (LS) column on the magnetic holder. The column was washed four times and the cells were collected as the negative fraction. The column was removed from the magnetic holder and the positive fraction was collected.

Sphere forming efficiency {#s4_3}
-------------------------

The sphere forming ability of CD133 sorted cells was determined by resuspending cells in serum-free conditional medium at a density of 20,000; 10,000; 5,000; or 2,000 cells/well in 6--well low adherence plates (Corning, CA, USA). All experiments were conducted in triplicate. Plates were maintained at 37°C in humidified CO~2~ incubator and were fed every other day. After 10 days colonies were counted under the microscope in 10 fields per well.

Cytotoxic drug or radiation treatment {#s4_4}
-------------------------------------

Cells were grown to 70% confluency before treating with indicated drug or stress. Cells were irradiated in culture medium using a Faxitron^®^ cabinet X-ray system, 43855D (Faxitron X-ray Corporation, Lincolnshire, IL, USA), at a central dose rate of 2 Gy/min. Cells were irradiated at the stated doses and harvested at the stated time points. Cells were treated with doxorubicin (Pharmacia/Pfizer, Sandwich, UK) or gefitinib (Tocris Bioscience, Bristol, UK), within the indicated dose range. All drugs were dissolved in dimethyl sulfoxide, and diluted in media immediately before use. Vehicle controls were included in all experiments.

Analysis of cytotoxicity {#s4_5}
------------------------

Cells were trypsinised into single cells and seeded in quadruplet in opaque 96-well plates (Corning, CA, USA) at 500 cells/well. Serial dilutions of doxorubicin, gefitinib, or ionising radiation were added to the appropriate cells the following day or as indicated. Dose-response curves were generated 48 hours after exposure. Cytotoxicity was measured using the CellTiterGlo® Luminescent Cell Viability Assay (Promega, Madison, USA), which quantifies the number of viable cells in culture based on quantification of ATP present. Luminescence was recorded by luminometer (Viktor3, PerkinElmer, Massachusetts, USA). Data was averaged and normalized against the average signal of untreated/vehicle control treated samples.

Colony formation assay {#s4_6}
----------------------

Cells were trypsinised into single cells and seeded at 500 cells/10 cm plate. The cells were treated with the indicated dose of doxorubicin or ionising radiation whilst in suspension. Plates were incubated at 37°C in humidified CO~2~ incubator until colonies were visible. Growth media was changed once a week. The colonies were fixed by incubating with ice-cold methanol for 5 minutes at room temperature. Colonies were stained with Giemsa stain (Invitrogen, Paisley, UK) according to the manufacturer\'s instruction. The total number of colonies was counted.

Invasion assay {#s4_7}
--------------

The cell invasion ability of isolated cells was determined using the QCM™ collagen-based cell invasion assay kit (Millipore, MA, USA) according to the manufacturer\'s instructions. Cells were seeded into the upper inserts at 1×10^5^ cells/insert in William\'s E Medium with GlutaMAX. Outer wells were filled with William\'s E Medium with GlutaMAX. Cells were incubated at 37°C with 5% CO~2~ for 48 hours. The non-invading cells were removed. Cells that migrated through the gel insert to the lower surface were stained and quantified by colorimetric measurement at 560 nm.

Chick embryo chorioallantoic membrane assay {#s4_8}
-------------------------------------------

Fertilised ISABrown layer strain chicken eggs (Roslin Institute Poultry Unit) were incubated in a humidified rotary incubator at 37°C. On day 3, a small window was opened in the shell after removal of 2-3 ml of albumin, to detach the CAM from the shell and to disclose the underlying CAM vessels. The window was sealed with tape and incubation was continued until day 7. On day 7, single cell suspensions of adherent cells and mammospheres were labelled with PKH26 (Sigma-Aldrich, MO, USA), a red fluorescent live cell membrane dye, according to manufacturer\'s instructions. Viable 10^5^ (n=4) cells were suspended in a 1:1 mixture of serum-free media:matrigel, and 25 μL was inoculated directly onto the CAM. The embryos were resealed and incubated without turning. At day 10, tumour growth and location were determined.

Protein detection {#s4_9}
-----------------

Cells were lysed in urea lysis buffer (7 M urea, 0.1 M DTT, 0.05 % Triton X-100, 25 mM NaCl, 20 mM Hepes pH 7.5). Equal amounts of protein were separated by SDS polyacrylamide gel electrophoresis (SDS PAGE), transferred to Hybond-C nitrocellulose membrane (Amersham Pharmacia Biotech, Buckinghamshire, UK). Non-specific antibody binding was blocked by incubating membranes in 5 % milk/ 1 % β-glycerophosphate/ PBST for 1 hr at room temperature. β-glycerophosphate is a serine/threonine phosphatase inhibitor critical for the retention of phosphorylation modifications. Membranes were probed with appropriate primary antibody for 3 hr at room temperature or overnight at 4°C. Membranes were washed once in PBST. Specific antibody binding was detected by incubating membranes for 1 hr at room temperature with a secondary horseradish peroxidase (HRP) conjugated antibody diluted 1:1000 in 5 % milk/ 1% β-glycerophosphate/ PBST. Following three 15 min washes in PBST, membranes were treated with ECL chemiluminescent detection system (2 ml /blot, 1:1 ratio ECL I : ECL II) and protein bands were visualized by exposure to X-ray film (Kodak). Antibodies against Primary antibodies were β-actin, γ-H2AX, EGFR and phosphor-EGFR (Ser1047) (Abcam), β-catenin, E-cadherin and fibronectin (BD Biosciences), AKT, phospho-AKT (Ser473) and phospho-p53 (Ser15) (Cell Signaling), MDM2 (4B2) and p53 (DO1) (Moravain Biotechnology), phospho-EGFR (Tyr 1173) (SantaCruz Biotechnology). Secondary antibodies were HRP-conjugated rabbit anti-mouse IgG and swine anti-rabbit IgG (DakoCytomation).

Subcellular proteome extraction {#s4_10}
-------------------------------

The Subcellular Proteome Fractionation Kit (Thermo Scientific) was used to extract proteins from mammalian cells according to their subcellular localisation. All fractions were stored at −70°C and analysed by immunoblotting (see above).

RNA extraction and reverse transcription PCR analysis {#s4_11}
-----------------------------------------------------

Total cellular RNA was extracted using RNeasy^®^ kit (Qiagen, CA, USA) and RNA quality was determined by A~260~ measurement. Semi-quantitative RT-PCR analysis of mRNA expression of stem cell specific genes including *Oct4, Nanog* and *STAT3* was performed using HotStar *Taq* polymerase (Qiagen, CA, USA) and specific primers (Table [4](#T4){ref-type="table"}.)

###### Top biological functions of differentially expressed genes in J3T spheres compared to adherent cells (FDR = 0.005)

                                                    p-Value                Number of molecules
  ------------------------------------------------- ---------------------- ---------------------
  **Diseases and Disorders**                                               
  Genetic Disorder                                  2.66E-20-- 9.88E-04    2087
  Cancer                                            1.29E-17 -- 9.49E-04   1254
  Gastrointestinal Disease                          1.29E-17 -- 8.67E-04   1215
  Developmental Disorder                            2.84E-12 -- 1.10E-11   142
  Infectious Disease                                3.30E-12 -- 4.57E-04   466
  **Molecular & Cellular Functions**                                       
  Cell Cycle                                        1.40E-28 -- 9.70E-04   544
  Protein Synthesis                                 5.48E-20 -- 5.91E-04   308
  Cell Death                                        1.17E-19 -- 9.57E-04   985
  RNA Post-translational Modification               1.03E-17 -- 7.49E-04   171
  DNA Replication, Recombination and Repair         5.41E-17 -- 9.25E-04   461
  **Physiological System Development & Function**                          
  Organismal Survival                               1.56E-09 -- 4.94E-09   328
  Organismal Development                            9.61E-07 -- 9.12E-04   267
  Connective Tissue Development and Function        1.47E-05 -- 5.88E-04   162
  Tissue Development                                1.47E-05 -- 7.01E-04   151
  Tumour Morphology                                 9.20E-05 -- 9.20E-05   82

Real-time quantitative PCR {#s4_12}
--------------------------

Total RNA was reverse transcribed using the omniscript RT Kit (Qiagen, CA, USA) according to the manufacturer\'s instruction. Real-time PCR was performed on 50 ng of amplified RNA using a Stratagene Mx3000p qPCR system (Aligent, CA, USA), using the Platinum^®^ SYBR^®^ Green qPCR SuperMix-UDG according to manufacturer\'s instruction (Invitrogen, CA, USA). Relative gene expression levels of *TNFAIP6, EDNRA, NGR1* and *IL8* were obtained by normalization to the expression levels of housekeeping genes (*MRPS7*, *GAPDH*). Primer sequences are shown in Table [5](#T5){ref-type="table"}.

Gene expression profiling using cDNA microarrays {#s4_13}
------------------------------------------------

###### Top ten upregulated genes in J3T spheres compared to adherent cells (FDR = 0.005)

  Gene Symbol   Gene Name                                             Accession Number   Gene Ontology                                       Fold Change
  ------------- ----------------------------------------------------- ------------------ --------------------------------------------------- -------------
  EDNRA         endothelin receptor type A                            P25101             G-protein coupled receptor                          78.64
  CXCR7         chemokine (C-X-C motif) receptor 7                    P25106             G-protein coupled receptor                          72.45
  TNFAIP6       Tumor Necrosis Factor, Alpha-Induced Protein 6        P98066             extracellular matrix stability and cell migration   44.29
  COL3A1        collagen, type III, alpha 1                           P02461             Component of connective tissues                     37.14
  FAP           fibroblast activation protein, alpha                  Q12884             Wound healing                                       28.68
  LUM           lumican                                               P51884             Extra cellular matrix structural constituent        27.57
  IGFBP2        insulin-like growth factor binding protein 2, 36kDa   P18065             Inhibition of IGF-mediated growth and development   27.13
  LMCD1         LIM and cysteine-rich domains 1                       Q9NZU5             Transcription corepressor activity                  21.43
  CDO1          cysteine dioxygenase, type I                          Q16878             Cysteine dioxygenase activity                       20.65
  EGR1          early growth response 1                               P18146             Transcriptional regulator                           20.57

RNA was isolated from frozen cell pellets of untreated (0 Gy) and irradiated (5 Gy) J3T spheres and adherent cells, with TriReagent (Sigma-Aldrich, MO, USA) according to manufacturer\'s instruction. Four independent replicates were used for each sample. Total RNA quality was determined by Bioanalyser (Agilent, CA, USA) before further manipulation. Complementary RNA preparation and hybridization were performed by ARK-Genomics (Edinburgh, UK) using Affymetrix GeneChip® Canine Genome 2.0 Array (42,800 probe sets). Basic data analysis was performed using the Partek Genomics Suite (Partek Inc, MO, USA). Pathway analysis was performed using Ingenuity Pathway Analysis (IPA, Ingenuity systems; <https://www.analysis.ingenuity.com>). Genes from the dataset that met the log ratio cut-off of 1.5 were considered for the analysis. To identify the most relevant canonical pathways, we selected those that were statistically significant with a *p* value \< 0.005. All microarray data has been submitted to the NCBI Gene Expression Omnibus database.

Statistical analysis {#s4_14}
--------------------

Data were expressed as a mean ±SD. Statistical analysis was performed with Minitab® statistical software (PA, USA) using analysis of variance and student\'s t test or mann-whitney test. The criterion for significance was p \< 0.05 for all comparisons.

CONCLUSIONS {#s5}
===========

In summary, our findings demonstrate that CSCs exist in the canine glioma cell line, J3T and the human glioma cell line, LN18. These cells are more invasive, more tumourigenic and more resistant to chemotherapy and irradiation compared with non-CSC glioma cells. Global gene expression analysis has demonstrated that the gene expression profiles of these subpopulations of glioma cells significantly differ, and we have consequently shown differences in the p53 and EGFR signaling pathways. Activators of the EGFR pathway were over-expressed in CSCs compared to non-CSCs, and we subsequently showed that CSCs were more sensitive to the effect of gefitinib, which enhanced radiosensitivity and increased cytotoxicity.
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